COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Cohort Study for Active Surveillance of COVID-19 Vaccines’ Side Effects

Abanoub Riad 1,2, Holger Schünemann 1, Sameh Attia 1,4, Tina Poklepović Perićić 5, Marija Franka Žuljević 6, Mikk Jürisson 7, Ruth Kalda 7, Katrin Lang 7, Sudhakar Morankar 8, Elisa Ali Yusuf 8, Mohamed Mekhemar 8, Anthony Danso-Appiah 9, Ahmad Sofi-Mahmudi 11, Giordano Pérez-Gaxiola 12, Arkadiusz Dziedzic 13, João Apóstolo 14, Daniela Cardoso 14, Janja Marc 15,16, Mayte Moreno-Casbas 17, Charles Shey Wiysonge 18, Amir Qaseem 19, Anna Gryschek 20, Ivana Tadić 21, Salman Hussain 1, Mohammed Ahmed Khan 22, Jitka Klugarova 1,2,23,24, Andrea Pokorna 1,2,23,24, Michal Koščík 2,25 and Miloslav Klugar 1,2,23,24,*

1 Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic), Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic; abanoub.riad@med.muni.cz (A.R.); mohammad.hussain@med.muni.cz (S.H.); klugarova@med.muni.cz (J.K.); apokorna@med.muni.cz (A.P.)
2 Department of Family Medicine and Public Health, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic; koscik@med.muni.cz
3 Department of Health Research Methods, Evidence, and Impact, McMaster University Health Sciences Centre, Room 2C16, 1280 Main Street West, Hamilton, ON L8N 4K1, Canada; schuneh@mcmaster.ca
4 Department of Oral and Maxillofacial Surgery, Justus-Liebig-University, Klinikstrasse 33, 35392 Giessen, Germany; sameh.attia@dentist.med.uni-giessen.de
5 Department of Research in Biomedicine and Health, University of Split School of Medicine, Šoltanska 2, 21000 Split, Croatia; tina.poklepovic@meist.hr
6 Department of Medical Humanities, University of Split School of Medicine, Šoltanska 2, 21000 Split, Croatia; marija.franka@gmail.com
7 Department of Family Medicine and Public Health, University of Tartu, Ravila 19, 50411 Tartu, Estonia; mikk.jurisson@ut.ee (M.J.); ruth.kalda@ut.ee (R.K.); katrin.lang@ut.ee (K.L.)
8 Faculty of Public Health, Institute of Health, Jimma University, Abo Jifar I Street, 378 Jimma, Ethiopia; morankar5@yahoo.com (S.M.); elias.yusuf@gmail.com (E.A.Y.)
9 Clinic for Conservative Dentistry and Periodontology, School of Dental Medicine, Kiel University, Arnold-Heller-Str. 3, Haus B, 24105 Kiel, Germany; mekhemar@konspar.uni-kiel.de (M.M.)
10 Department of Epidemiology and Disease Control, School of Public Health, University of Ghana, Accra LG 25, Ghana; adanso-appiah@ug.edu.gh
11 Cochrane Iran Associate Centre, National Institute for Medical Research Development, Tehran 16846, Iran; sofimahmudi@research.ac.ir
12 Department of Evidence Based Medicine, Sinaloa Pediatric Hospital, Cochrane Mexico, Calle Constitución 530, Jorge Almada, 70200 Culiacán, Mexico; giorjano@cochrane.mx
13 Department of Conservative Dentistry with Endodontics, Medical University of Silesia, 40-055 Katowice, Poland; adziedzic@sum.edu.pl
14 Health Sciences Research Unit: Nursing, Portugal Centre for Evidence-Based Practice: JBI Centre of Excellence, Nursing School of Coimbra, 3004-011 Coimbra, Portugal; apostolos@esenfc.pt (J.A.); dcardoso@esenfc.pt (D.C.)
15 Faculty of Pharmacy, University of Ljubljana, Aškerčeva Cesta 7, 1000 Ljubljana, Slovenia; janja.marc@ff.uni-lj.si
16 Institute of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, Zaloška cesta 2, 1000 Ljubljana, Slovenia
17 Nursing and Healthcare Research Unit (Investén-isciii), Instituto de Salud Carlos III, 28029 Madrid, Spain; mmomoreno@isciii.es
18 Cochrane South Africa, South African Medical Research Council, Cape Town 7501, South Africa; charles.wiysonge@mrc.ac.za
19 American College of Physicians, 190 N Independence Mall W, Philadelphia, PA 19106, USA; aqaseem@acponline.org
20 Department of Nursing in Collective Health, School of Nursing, University of São Paulo, São Paulo 419, Brazil; gryshek@usp.br

Citation: Riad, A.; Schünemann, H.; Attia, S.; Perićić, T.P.; Žuljević, M.F.; Jürisson, M.; Kalda, R.; Lang, K.; Morankar, S.; Yusuf, E.A.; et al.
COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines' Side Effects. Int. J. Environ. Res. Public Health 2021, 18, 7859. https://doi.org/10.3390/ijerph18157859

Academic Editor(s): Paul B. Tchounwou
Received: 27 May 2021
Accepted: 20 July 2021
Published: 25 July 2021
Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Abstract: Background: Coronavirus disease (COVID-19) vaccine-related side effects have a determinant role in the public decision regarding vaccination. Therefore, this study has been designed to actively monitor the safety and effectiveness of COVID-19 vaccines globally. Methods: A multi-country, three-phase study including a cross-sectional survey to test for the short-term side effects of COVID-19 vaccines among target population groups. In the second phase, we will monitor the booster doses’ side effects, while in the third phase, the long-term safety and effectiveness will be investigated. A validated, self-administered questionnaire will be used to collect data from the target population; Results: The study protocol has been registered at ClinicalTrials.gov, with the identifier NCT04834869. Conclusions: CoVaST is the first independent study aiming to monitor the side effects of COVID-19 vaccines following booster doses, and the long-term safety and effectiveness of said vaccines.

Keywords: cohort studies; cross-sectional studies; COVID-19; drug-related side effects and adverse reactions; health personnel; mass vaccination; prevalence

1. Introduction

Coronavirus disease (COVID-19) mass vaccination has been a chief priority for health systems globally, which needs to be accelerated in order to control the acute phase of the pandemic [1,2]. Nevertheless, vaccine hesitancy (VH)—which refers to the “delay in acceptance or refusal of vaccines despite the availability of vaccine services”—remains a serious challenge for vaccination strategies worldwide [3–5]. In 2019, the World Health Organization (WHO) declared VH as one of the top 10 global health threats, which is nourished by misinformation regarding vaccines’ effectiveness and safety [6].

Aversion to vaccines’ potential side effects is the most frequent cause of VH among various population groups [7,8]. Therefore, a recent systematic review revealed that raising public awareness of vaccines’ effectiveness, and honesty regarding their side effects, are vital strategies to improve vaccine uptake [9].

According to the Strategic Advisory Group of Experts on Immunization of the WHO (SAGE-WHO), distrust in the pharmaceutical industry is a contextual driver of VH, because vaccine manufacturers can be perceived as preferring their financial benefit over public health interest [10]. In both high-income and low-income settings, distrust of the pharmaceutical industry has been consistently and significantly higher among hesitant groups, and this is aggravated by a lack of transparency regarding public health plans [11–13].

Public health systems currently experience a novel and a unique challenge, due to the variety of vaccine manufacturers, and the high levels of public awareness about those manufacturers and their marketing strategies [8]. This unprecedented situation is predicted to create what we can refer to as “vaccine selectivity”, where individuals can prefer a certain type or brand of vaccine over others; this situation will increase the pressure on our weakened health systems and economies, and of course it can increase the VH levels as well [14].
The temporary suspension of the Oxford–AstraZeneca vaccine (AZD1222) (AstraZeneca plc, Cambridge, UK) and the Janssen vaccine (Ad26.COV2.S) (Johnson & Johnson (J&J), New Brunswick, NJ, US) due to reports of extremely rare side effects triggered public debates that might have adversely affected vaccination acceptance levels [15,16]. However, although the European and American drug regulators declared that the benefits of using these vaccines still outweigh their risks, very little is known about vaccine hesitancy and, probably, selectivity after these incidences [15,17].

Given the projected seasonality of COVID-19 transmission and the increasing number of its variants, vaccine manufacturers launched trials for booster doses that are predicted to be readily available by the fall of 2021 [18–20].

Independent (non-sponsored) studies with rigorous methods can successfully lead the unbiased pharmacovigilance efforts of COVID-19 vaccines globally [21–28]. Thus, in view of their independent nature and transparent design, these studies can play a key role in suppressing VH levels by enhancing public confidence in the vaccines.

**Objectives**

This project aims to actively monitor the side effects and effectiveness of COVID-19 vaccines worldwide. The primary objectives of the project include:

(a) To estimate the prevalence of both local and systemic side effects following each of the COVID-19 vaccines among healthcare workers (HCWs), teachers and academics (TAs), senior adults ≥ 65 years old (SAs), and minors ≤ 18 years old (MIs);

(b) To evaluate the potential demographic and medical risk factors for the frequency and intensity of side effects;

(c) To evaluate the long-term safety of COVID-19 vaccines.

The secondary objectives include:

(a) To evaluate the relative effectiveness and safety of COVID-19 vaccines in relation to one another;

(b) To evaluate the impact of palliative medications used by the vaccinated individuals for short-term side effect resolution.

**2. Materials and Methods**

**2.1. Design**

This project is composed of three main phases: (a) a cross-sectional survey for the short-term side effects of COVID-19 vaccines; (b) a prospective cohort study for the safety of COVID-19 vaccines following booster doses; and (c) a prospective cohort study for the long-term safety and effectiveness of COVID-19 vaccines.

**2.1.1. Phase A**

A validated, self-administered questionnaire will be developed and delivered online to the target population groups (HCWs, TAs, SAs, and MIs). In certain circumstances, telephone interviews and paper questionnaires will be used instead of the online questionnaire in order to adapt to the local setting. The questionnaire will inquire about the short-term side effects following either the first dose, the second dose, or both doses of the COVID-19 vaccine. The side effects will be classified as local or systemic, and their onset, duration, and intensity will be self-assessed and self-reported by the participating subjects. This phase is planned to take place until 31 December 2021.

**2.1.2. Phase B**

A validated, self-administered questionnaire will be developed and delivered online to the volunteers who participated in Phase A and expressed their interest in reporting on
their long-term outcomes. The short-term side effects following booster doses will be investigated in this phase. This phase is tentatively planned to take place from October 2021 until April 2022.

2.1.3. Phase C

A validated, self-administered questionnaire will be developed and delivered online to the volunteers who participated in Phase A and expressed their interest in self-reporting their long-term outcomes. The vaccines’ effectiveness and safety will be monitored, and this phase will last for five consecutive years, starting from January 2022.

2.2. Population

In Phase A, a pragmatic approach will be used, tracking each target population group according to individual governments’ distributional plans, which in most countries went from HCWs, to SAs, to TAs, to MIs. The sample of Phases B and C will be pre-identified based on the outcomes of Phase A.

If more than 368 of the Phase A participants show their interest in joining Phase B, no additional recruitment will be required. If less than 368 of the Phase A participants show their interest in participating in Phase B, additional recruitment will be carried out, targeting HCWs who will receive booster doses. In case of the emergence of special side effects after booster doses, additional recruitment of a sample of HCWs will be required.

2.2.1. Inclusion Criteria

- HCWs, TAs, SAs, and MIs who received a COVID-19 vaccine in the post-authorization phase;
- The recently vaccinated individuals who received their vaccine dose within the previous 30 days will be prioritized to be invited for the study, even though the study will not be limited to the recently vaccinated individuals;
- Participating subjects should be at least 18 years old in order to give their informed consent independently, or in case of the minors (below 18 years old), their caregivers will be asked to give their informed consent.

2.2.2. Exclusion Criteria

- HCWs, TAs, SAs, and MIs who received the COVID-19 vaccines as part of phase III clinical trials.

2.2.3. Sample Size

The pragmatic sample size for each target group in each country will be calculated using Epi Info™ version 7.2.4 (CDC, Atlanta, GA. 2020). The formula of population survey studies will be used to achieve a 5% margin of error and a 95–99% confidence level [29]. The expected frequency (outcome probability) is assumed to be 60%, as the prevalence of side effects following COVID-19 vaccines ranged between 62% and 93% in our previous studies [21,22] (Figure 1).
Figure 1. Sample size of healthcare workers (HCWs) in the Czech Republic—Epi-Info™ version 7.2.4. Population size: Total number of healthcare workers in the Czech Republic in 2017 [30]. Expected frequency: The overall prevalence of side effects following COVID-19 vaccines ranged between 62% and 93%; therefore, 60% was assumed as a threshold. Acceptable margin of error: The permissible level for all CoVaST groups will be 5%. Design effect: One—per the recommendation of the CDC for simple sampling [29]. Clusters: One—per the recommendation of the CDC for simple sampling [29]. The pragmatic sample size is 368–635 (CI 95%–99%).

2.3. Instrument

The questionnaire will be based on the growing evidence of COVID-19 vaccines’ side effects, and adverse reactions and will be updated and validated accordingly. The questionnaire consists of four categories: (a) demographic data (age, gender, height, weight, profession, and geographic region); (b) medical anamneses (chronic illnesses, medications, smoking, and alcohol consumption); (c) COVID-19-related anamneses (type of vaccine, number of vaccine doses, dates of vaccine doses, previous infection, and diagnosis date); and (d) vaccine side effects (local side effects, systemic side effects, onset, and duration) Table S1.

The multi-linguistic versions of the instrument will be produced through a pragmatic workflow for translation and cultural adaptation [31]. The current instrument is designed and validated for the HCWs group. The instrument will be validated for the other two populations of interest (OAs and TAs) by a validation process using a panel of experts, with four experts from the targeted population and four experts with a background in public health, epidemiology, infectious disease, and vaccination.

Two native speakers of the target language with a high level of English proficiency will translate the instrument independently. An expert panel composed of three members (the two forward translators, and a third native speaker with a biomedical background and an advanced grasp of the English language) will review the two translated versions, and will resolve discrepancies between them, aiming to generate a harmonized final version. The working version will undergo reliability testing through test–retest. In the test–retest, a minimum of 10 volunteers should fill in the questionnaire twice, at least two weeks apart.

2.4. Recruitment

Data will be collected in two phases via an online, validated, self-administered questionnaire. Although the data collection strategies may differ across the globe, the target groups are recommended to be approached by governmental, professional, and university networks.
2.4.1. Phase A

A.1. HCWs will be approached by medical and healthcare chambers and/or healthcare professional organizations, and the snowballing technique will be applied;

A.2. Senior adults (≥65) will be approached by the “university of the third age”, by the professional medical association of “young general practitioners”, and by professional organizations for older adults, and the snowballing technique will be applied;

A.3. School teachers will be approached by the networks of educational institutions, while university teachers will be approached via all major universities, and the snowballing technique will be applied;

A.4. Minors (≤18) will be principally approached through their schools, where their parents (or guardians) will be invited to fill in the questionnaire on behalf of their children.

Data collection for the A.1, A.2, A.3, and A.4. population groups will be adjusted according to each participating country’s local setting.

2.4.2. Phase B and C

Volunteers who participate in Phase A and express their interest in self-reporting their long-term side effects will be approached again. The vaccine effectiveness and side effects following booster doses will be investigated in Phase B. Phase C will take place for five consecutive years, starting from 2022.

2.5. Timeline

As the local timelines are dependent on the setting of each participating country—including governments’ distribution plans, availability of vaccines, and administrative processes—the proposed timeline is deemed to guide the overall CoVaST progress (Table 1).

| Phase | Stage | Population | Schedule               |
|-------|-------|------------|------------------------|
| Phase A | Stage A.1. | HCWs | May–August 2021 |
|       | Stage A.2. | SAs   | June–December 2021    |
|       | Stage A.3. | TAs   | June–December 2021    |
|       | Stage A.4. | MIs   | June–December 2021    |
| Phase B | Stage B.1. | HCWs | October 2021–February 2021 |
|       | Stage B.2. | SAs   | November 2021–April 2022 |
|       | Stage B.3. | TAs   | November 2021–April 2022 |
|       | Stage B.4. | MIs   | November 2021–April 2022 |
| Stage C | Stage C.1. | HCWs, SAs, TAs, MIs | January–December 2022 |
|       | Stage C.2. | HCWs, SAs, TAs, MIs | January–December 2023 |
|       | Stage C.3. | HCWs, SAs, TAs, MIs | January–December 2024 |
|       | Stage C.4. | HCWs, SAs, TAs, MIs | January–December 2025 |
|       | Stage C.5. | HCWs, SAs, TAs, MIs | January–December 2026 |

HCWs = Healthcare Workers; SAs = Senior Adults; TAs = Teachers and Academics; MIs = Minors.

2.6. Ethics

The study was reviewed and approved by the Ethics Committee of the Faculty of Medicine at Masaryk University on 19 May 2021 (Ref. 26/2021). Ethical clearance will be secured from a designated institutional review board in each participating country before commencement of the study.

Digital informed consent will be obtained from each participant prior to participation. The participants will be allowed to withdraw from the study at any moment without justification, and no data will be saved before the participants submit their answers completely.
2.7. Analysis

Descriptive statistics will be performed to check the normality of data distribution, and to present the frequencies and percentages of dependent variables (side effects) and independent variables (demographic data, medical anamneses, and COVID-19-related anamneses). Inferential statistics will be performed to evaluate the potential association of each side effect and the suggested demographic and medical risk factors. All tests will be performed using SPSS 27 (IBM Corp, Armonk, NY, USA), and the significance level cutoff will be set at $p \leq 0.05$ [32].

3. Registration and Dissemination

The study protocol has been registered with the US National Library of Medicine registry (ClinicalTrials.gov), with the identifier NCT04834869 [33]. The ClinicalTrials.gov record will be regularly updated by the project’s principal investigators, and any deviations from the protocol will be mentioned and justified a priori in the electronic record, and in the manuscript of the final study.

The investigators aim to disseminate the results of the project in peer-reviewed journals on a regular basis. For the results of phase A, the international data for each target group will be published once the data collection is completed. Meanwhile, national data of each participating center will be published as interim results. For the results of phase B, the international data for each target group will be published once the data collection is completed. For the results of phase C, the international data for all target groups will be published on an annual basis once the data collection is completed.

4. Discussion

Post-marketing evaluation of vaccines’ safety has typically relied on voluntary reporting of side effects by health care professionals, vaccinated individuals, and caregivers. While there is a surging demand for rigorous pharmacovigilance systems, with active surveillance designs rather than the traditional passive surveillance, a very limited number of high-income countries have managed to develop such systems so far [34].

The United Kingdom (UK) is one of the leading countries in this field, due to its early efforts in developing active surveillance systems for the safety of diphtheria/tetanus/pertussis (DTP) and measles/mumps/rubella (MMR) vaccines since the early 1990s [35]. In terms of COVID-19 vaccines’ safety, the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK has adopted an innovative hybrid system that includes: (a) enhanced passive surveillance through the Yellow Card scheme, where members of the public and healthcare professionals voluntarily report suspected side effects; (b) targeted active monitoring using the Yellow Card scheme; and (c) formal epidemiological studies, such as the OpenSAFELY 17 Collaborative and COVID Symptom Study app [25,36,37].

The results of post-marketing studies may differ to various degrees from the outcomes of phase III trials, where apparently healthy volunteers are usually recruited following strict criteria. Riad et al. found that the overall prevalence of Pfizer–BioNTech (Pfizer Inc.: New York City, US) COVID-19 vaccine side effects among recently vaccinated HCWs in the Czech Republic was relatively higher than those reported by the manufacturer [21]. Similarly, the side effects of the Moderna COVID-19 vaccine and the CoronaVac vaccine were more prevalent among HCWs in the US and Turkey, respectively, than the manufacturers’ reports [22,27]. On the other hand, Menni et al. found that the side effects of the Pfizer–BioNTech and Oxford–AstraZeneca COVID-19 vaccines occurred less frequently among a large cohort in the UK than those reported in the phase III trials [25].

The demographic and medical risk factors for side effects’ frequency and intensity are not usually reported by phase III trials, as they are not necessarily outcomes of interest during this stage. Therefore, post-marketing studies are in an ideal position to confirm or refute suggested risk factors, using large datasets of self-reported outcomes. For example,
all post-marketing studies of mRNA vaccines found that the frequency of side effects following the second dose is higher than after the first dose [21,23–25]. The phase III trials displayed the same pattern; therefore, the post-marketing studies only came to confirm this preliminary finding [38,39]. Female gender was consistently associated with an increased risk of side effects following different types of COVID-19 vaccines; interestingly, the gender-based differences were reported by manufacturers [21–23,25,28].

As more COVID-19 vaccines are currently in the pipeline of clinical trials and authorization, readily available instruments for active surveillance will be much needed in order to shorten the time period of post-marketing investigation by academic institutions. Moreover, the prospective booster doses’ safety should be evaluated in relatively shorter periods of time, in order to relieve our weakened healthcare systems. Therefore, the CoVaST project aims to provide an international infrastructure for active surveillance of booster doses’ side effects and the long-term safety and effectiveness of COVID-19 vaccines.

Strengths and Limitations

To the best of the authors’ knowledge, this is the first multinational study aiming to monitor the safety of various COVID-19 vaccines, especially following booster doses. Another strong point of this study is its unified evaluation instrument, target groups, and methods, which will be used in all participating countries, and should maximize the results’ internal validity. Recruiting HCWs is intended to limit the reporting bias that is naturally predicted in this survey-based study, due to the fact that HCWs retain high levels of health literacy and scientific interest. This study is one of the early-registered studies that are concerned with the long-term safety of COVID-19 vaccines, and their effectiveness.

In general, this study is limited by the heterogeneous time span between vaccination and survey commencement across the participating countries; therefore, subgroup analysis according to the time span will be carried out during data analysis. One more limitation is recall bias, as in various countries, vaccination covered the majority of population who intended to be vaccinated. Due to the recruitment of participants who received the vaccine in the first half of 2021, there is a possibility of recall bias when filling out the questionnaire. Since COVID vaccination is a hot topic worldwide, we assume that participants could remember all experienced side effects well.

5. Conclusions

The side effects of COVID-19 vaccines require active surveillance in the post-authorization phase, as the side effects can potentially impact decisions regarding vaccination. CoVaST, as a multi-national study, aims to evaluate the short-term and long-term side effects and effectiveness of various COVID-19 vaccines.

Supplementary Materials: The following are available online at www.mdpi.com/10.3390/ijerph18157859/s1: Table S1: CoVaST Instrument.

Author Contributions: Conceptualization, A.R. and M.K. (Miloslav Klugar); methodology, A.R. and M.K. (Miloslav Klugar); validation, H.S., S.A., T.P.P., M.F.Ž., M.J., R.K., K.L., S.M., E.A.Y., M.M., A.D.-A., A.S.-M., G.P.-G., A.D., J.A., D.C., J.M., M.M.-C., C.S.W., A.Q., A.G., I.T., M.A.K., J.K., A.P., and M.K. (Michal Koščík); writing—original draft preparation, A.R. and M.K. (Miloslav Klugar); writing—review and editing, H.S., S.A., T.P.P., M.F.Ž., M.J., R.K., K.L., S.M., E.A.Y., M.M., A.D.-A., A.S.-M., G.P.-G., A.D., J.A., D.C., J.M., M.M.-C., C.S.W., A.Q., A.G., I.T., M.A.K., J.K., A.P., and M.K. (Michal Koščík); project administration, A.R. and M.K. (Miloslav Klugar); funding acquisition, M.K. (Miloslav Klugar). All authors have read and agreed to the published version of the manuscript.

Funding: This study protocol preparation was funded by Masaryk University, grant numbers MUNI/IGA/1543/2020 and MUNI/A/1608/2020.

Institutional Review Board Statement: The study will be conducted in accordance with the guidelines of the Declaration of Helsinki, and was approved by the Ethics Committee of the Faculty of Medicine, Masaryk University Ref. 26/2021 on 19 May 2021.
Informed Consent Statement: Digital informed consent will be obtained from all subjects involved in the study.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments: This work is dedicated to the more than three million worldwide fatalities, and their families, who have fallen victim to COVID-19.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. World Health Organization (WHO). COVID-19 Vaccine Country Readiness and Delivery. COVAX. Available online: https://www.who.int/activities/act-accelerator/covax/covid-19-vaccine-country-readiness-and-delivery (accessed on 7 May 2021).
2. Attia, S.; Howaldt, H.-P. Impact of COVID-19 on the Dental Community: Part I before Vaccine (BV). J. Clin. Med. 2021, 10, 288, doi:10.3390/jcm1002088.
3. Butler, R.; MacDonald, N.E. Diagnosing the determinants of vaccine hesitancy in specific subgroups: The Guide to Tailoring Immunization Programs (TIP). Vaccine 2015, 33, 4176–4179, doi:10.1016/j.vaccine.2015.04.038.
4. Harrison, E.A.; Wu, J.W. Vaccine confidence in the time of COVID-19. Eur. J. Epidemiol. 2020, 35, 325–330, doi:10.1007/s10654-020-00634-3.
5. Dror, A.A.; Eisenbach, N.; Taiber, S.; Morozov, N.G.; Mizrachi, M.; Zigron, A.; Srouji, S.; Sela, E. Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur. J. Epidemiol. 2020, 35, 775–779, doi:10.1007/s10654-020-00671-y.
6. World Health Organization (WHO). Ten Threats to Global Health in 2019. Newsroom. Available online: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 (accessed on 7 May 2021).
7. Luyten, J.; Bruyneel, L.; van Hoek, A.J. Assessing vaccine hesitancy in the UK population using a generalized vaccine hesitancy survey instrument. Vaccine 2019, 37, 2494–2501, doi:10.1016/j.vaccine.2019.03.041.
8. Fisher, K.A.; Bloomstone, S.J.; Walder, J.; Crawford, S.; Fouayzi, H.; Mazor, K.M. Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults. Ann. Intern. Med. 2020, 173, 964–973, doi:10.7326/M20-3569.
9. Jarrett, C.; Wilson, R.; O’Leary, M.; Eckersberger, E.; Larson, H.J. Strategies for addressing vaccine hesitancy-A systematic review. Vaccine 2015, 33, 4180–4190, doi:10.1016/j.vaccine.2015.04.040.
10. Strategic Advisory Group of Experts on Immunization (SAGE). Vaccine Hesitancy Survey Questions Related to SAGE Vaccine Hesitancy Matrix. Available online: https://www.who.int/immunization/programmes_systems/Survey_Questions_Hesitancy.pdf (accessed on 14 March 2021).
11. Greenberg, J.; Dubé, E.; Driedger, M. Vaccine Hesitancy: In Search of the Risk Communication Comfort Zone. PLoS Curr. 2017, 9, doi:10.1371/currents.outbreaks.0561a01117a1d19596e24949e8690b.
12. Dinga, J.N.; Sinda, L.K.; Titanji, V.P.K. Assessment of vaccine hesitancy to a covid-19 vaccine in cameroonian adults and its global implication. Vaccines 2021, 9, 1–14, doi:10.3390/vaccines9020175.
13. Diaz Crescitielli, M.E.; Ghirotto, L.; Sismondo, H.; Sarli, L.; Artioli, G.; Bassi, M.C. A meta-synthesis study of the key elements involved in childhood vaccine hesitancy. Public Health 2020, 180, 38–45, doi:10.1016/j.puhe.2019.10.027.
14. Six Ways to Better Understand COVID-19 Vaccine Hesitancy by Surgo Ventures Medium. Available online: https://surgoventures.medium.com/six-ways-to-better-understand-covid-19-vaccine-hesitancy-3689dfd65b86 (accessed on 24 March 2021).
15. Mahase, E. Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency. BMJ 2021, 372, n774, doi:10.1136/bmj.n774.
16. McEvoy, J. European Healthcare Workers Are Refusing AstraZeneca Vaccine Over Efficacy Concerns. Forbes. Available online: https://www.forbes.com/sites/jemimamcevoy/2021/02/21/european-healthcare-workers-are-refusing-astrazeneca-vaccine-over-efficacy-concerns/?sh=547867806520 (accessed on 19 May 2021).
17. European Medicines Agency (EMA). COVID-19 Vaccine AstraZeneca: Benefits Still Outweigh the Risks Despite Possible Link to Rare Blood Clots with Low Blood Platelets. Available online: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots (accessed on 20 March 2021).
18. Institute for Health Metrics and Evaluation (IHME). COVID-19 model FAQs. COVID-19 Resources. Available online: http://www.healthdata.org/covid/faq (accessed on 18 May 2021).
19. Pfizer. Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants. Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-part-broad-development (accessed on 18 May 2021).
20. World-First COVID-19 Vaccine Booster Study Launches in UK-GOV.UK. Available online: https://www.gov.uk/government/news/world-first-covid-19-vaccine-booster-study-launches-in-uk (accessed on 20 May 2021).
21. Riad, A.; Pokorná, A.; Attia, S.; Klugarová, J.; Koščík, M.; Klugar, M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J. Clin. Med. 2021, 10, 1428, doi:10.3390/jcm10071428.
22. Riad, A.; Sağıroğlu, D.; Üstün, B.; Attia, S.; Klugar, M. Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study Among Healthcare Workers in Turkey. *SSRN Electron. J.* 2021, doi:10.2139/ssrn.3820571.

23. El-Shitany, N.A.; Harakeh, S.; Badr-Eldin, S.M.; Bagher, A.M.; Eib, B.; Almukadi, H.; Alghamdi, B.S.; Alahmadi, A.A.; Hassan, N.A.; Sindi, N.; et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study. *Int. J. Gen. Med.* 2021, 14, 1389–1401, doi:10.2147/IJGM.S310497.

24. Mathioudakis, A.G.; Ghrew, M.; Ustianowski, A.; Ahmad, S.; Borrow, R.; Papavasileiou, L.P.; Pettrakis, D.; Bakerly, N.D. Self-reported real-world safety and reactogenicity of covid-19 vaccines: A vaccine recipient survey. *Life* 2021, 11, 249, doi:10.3390/life11030249.

25. Menni, C.; Klaser, K.; May, A.; Polidori, L.; Capdevila, J.; Louca, P.; Sudre, C.H.; Nguyen, L.H.; Drew, D.A.; Merino, J.; et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. *Lancet Infect. Dis.* 2021, doi:10.1016/S1473-3099(21)00224-3.

26. Djanas, D.; Martini, R.D.; Putra, H.; Zanir, A.; Nindrea, R.D. Survey Data of COVID-19 Vaccine Side effects among Hospital Staff in a National Referral Hospital in Indonesia. *Data Br.* 2021, 107098, doi:10.1016/j.dib.2021.107098.

27. Kadali, R.A.K.; Janagama, R.; Peruru, S.; Gajula, V.; Madathala, R.R.; Chennaiahgari, N.; Malayala, S.V. Adverse effects of COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. *J. Med. Virol.* 2021, 1–10, doi:10.1002/jmv.26996.

28. Pagotto, V.; Ferloni, A.; Soriano, M.M.; Diaz, M.; Braguinsky, N.; Asprea, V.; Vidal, G.G.; Silveira, M.G.; Zingoni, P.; Aliperti, V.; et al. ACTIVE SURVEILLANCE OF THE SPUTNIK V VACCINE IN HEALTH WORKERS. *medRxiv.* 2021, doi:10.1101/2021.02.03.21251071.

29. Centers for Disease Control and Prevention (CDC). Population Survey or Descriptive Study. StatCalc User Guide. Available online: https://www.cdc.gov/epiinfo/userguide/statcalc/samplesize.html (accessed on 19 May 2021).

30. Institute of Health Information and St. DataLab. OpenSAFELY. University of Oxford for the The DataLab 2021. Available online: http://www.opensafely.org/ (accessed on 9 May 2021).

31. World Health Organization (WHO). Process of Translation and Adaptation of Instruments. Available online: https://www.who.int/substance_abuse/research_tools/translation/en/ (accessed on 25 December 2020).

32. SPSS Inc. IBM SPSS Statistics 27. Available online: https://www.ibm.com/support/pages/node/3006603 (accessed on 14 March 2021).

33. Miloslav Klugar, Abanoub Riad. COVID-19 Vaccines Safety Tracking (CoVaST). ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04834869 (accessed on 9 May 2021).

34. Huang, Y.L.; Moon, J.; Segal, J.B. A comparison of active adverse event surveillance systems worldwide. *Drug Saf.* 2014, 37, 581–596, doi:10.1007/s40264-014-0194-3.

35. Farrington, P.; Rush, M.; Miller, E.; Pugh, S.; Colville, A.; Flower, A.; Nash, J.; Morgan-Capner, P. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. *Lancet* 1995, 345, 567–569, doi:10.1016/S0140-6736(95)90471-9.

36. Medicines and Healthcare products Regulatory Agency (MHRA). Report of the Commission on Human Medicines Expert Working Group on COVID-19 Vaccine Safety Surveillance. Vigilance, Safety Alerts and Guidance. Available online: https://www.gov.uk/government/publications/report-of-the-commission-on-human-medicines-expert-working-group-on-covid-19-vaccine-safety-surveillance/report-of-the-commission-on-human-medicines-expert-working-group-on-covid-19-vaccine-safety-surveillance (accessed on 9 May 2021).

37. DataLab. OpenSAFELY. University of Oxford for the The DataLab 2021. Available online: https://www.opensafely.org/ (accessed on 9 May 2021).

38. Centres for Diseases Control and Prevention (CDC). REACTIONS and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine. Available online: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html (accessed on 7 March 2021).

39. Centres for Diseases Control and Prevention (CDC). Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine. Available online: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html (accessed on 2 April 2021).